Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kratos Defense & Security Solutions

UiPath

PagerDuty

Roblox

Block

Teradyne

Pursuing undervalued Cathie Wood stocks radiates a magnetic allure for investors aiming for a hefty financial breakthrough. The stocks favored by Wood are risky but grounded in foresight, offering tremendous long-term upside potential.

The 7 Most Undervalued Cathie Wood Stocks to Buy in September 2023

Ceres Nanosciences and Ginkgo Bioworks Partner to Bring Pathogen Monitoring Capabilities to Labs Around the World

Intellia Therapeutics

Cathie Wood likes to buy innovative and disruptive companies. She's been buying both Intellia Therapeutics and Ginkgo Bioworks recently.

Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double

BOSTON , Sept. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that Anna Marie Wagner, Senior Vice President of Corporate Development, is scheduled to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13 at 12:55 p.m.

Ginkgo Bioworks Announces Participation in Morgan Stanley 21st Annual Global Healthcare Conference

The biotech announced not one, but two partnerships in the past few days. One was with a top name in the tech sector.

Why Ginkgo Bioworks Stock Was a 34% Winner This Week

SANTIAGO, Chile and BOSTON , Aug. 31, 2023 /PRNewswire/ -- Exacta Bioscience, a biotech company that harnesses the power of nature and its microorganisms for crop protection, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Exacta is leveraging Ginkgo's end-to-end agricultural R&D services to run a fermentation optimization and scale-up program to enhance one of its crop protection products, FitoRoot ® , paving the way for large-scale commercialization. FitoRoot, a biostimulant product composed of three Bacillus strains, is designed to help crops better absorb water, nutrients and strengthen their defenses against abiotic stress.

Exacta Bioscience and Ginkgo Bioworks Announce Partnership to Optimize Exacta's Crop Protection Product

Ginkgo Bioworks stock soars on Google Cloud Partnership announcement. Is this a thesis changer?

Why Did This Cathie Wood Stock Soar 24% on Tuesday?

Ginkgo Bioworks Holdings has signed a five-year partnership with Google Cloud, providing funding and improving brand recognition. Ginkgo's disappointing Q2 earnings report highlights the need for additional streams of revenue and improved profitability, which the partnership with Google Cloud may help achieve. Their financial situation has become more tenable and as such we are upgrading our rating on DNA stock to neutral.

Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)

BOSTON , Aug. 30, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it will hold an Investor Day on Tuesday, October 3, 2023, beginning at 10:00 am ET. The event will feature conversations with Ginkgo's founders and senior management team across both its cell engineering and biosecurity businesses.

Ginkgo Bioworks to Host Investor Day on October 3, 2023

One of the best-performing stocks in today's market is biotech company Ginkgo Bioworks (NYSE: DNA ). Shares of DNA stock rocketed more than 20% higher in early afternoon trading.

DNA Stock Alert: Did Ginkgo Bioworks Just Become the Next Big AI Stock?

Esperion Therapeutics

OKYO Pharma Ltd

Opendoor

Are you trading penny stocks this week? Chances are that if you're reading this article, you have some intention of finding more info on cheap stocks.

Trading Penny Stocks This Week? 4 To Watch With Big News

Ginkgo and Google Cloud enter strategic five-year cloud and AI partnership Ginkgo to pioneer new large language models for biological engineering applications, powered by Google Cloud's Vertex AI platform Ginkgo intends to make Google its primary cloud services provider, benefiting from access to next-generation computational infrastructure and AI technologies Partnership to include funding from Google Cloud to enable Ginkgo's development of foundation models and fine-tuned applications BOSTON, Mass. and SUNNYVALE, Calif.

Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity

Corteva Inc

LanzaTech Global Inc

It's been more than a half century since humanity first learned to genetically modify organisms. While we're still learning new things every day about it, synthetic biology has now become commonplace in a multitude of industries.

The GMO Frontier: 3 Synthetic Biology Stocks for Your Must-Buy List

This collaboration aims to develop and deploy novel methods for pandemic surveillance among animals and livestock  BOSTON and NAIROBI, Kenya , Aug. 24, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading horizontal platform for cell programming and biosecurity, and the International Livestock Research Institute (ILRI), a leading organization on One Health approaches, today announced that they have entered into a Memorandum of Understanding with the intent to collaborate on pandemic surveillance work. The Consultative Group on International Agricultural Research (CGIAR) is a global research partnership for a food-secure future dedicated to transforming food, land, and water systems in the climate crisis.

Concentric by Ginkgo and CGIAR International Livestock Research Institute (ILRI) announce collaboration on pathogen surveillance

Archer Aviation

Ark Invest, the firm managed by Cathie Wood, announces its activity after each trading day. Last week, Ark Invest bought millions of shares of Archer Aviation, an air taxi business that could achieve liftoff in a couple of years.

2 Growth Stocks Cathie Wood Is Buying Hand Over Fist

Amneal Pharmaceuticals

FuboTV

Modular Medical

Are you on the hunt for the most promising penny stocks to invest in for 2023? Join the ever-expanding group of investors who are keen to leverage the booming market.

Penny Stocks To Buy? 4 To Watch With Big News This Month

The highly specialized healthcare company reported its second-quarter results. The easing of the Covid pandemic had a deleterious effect on its finances.

Why Ginkgo Bioworks Stock Plunged by 8% This Week

Gevo

Rigetti Computing

You've probably heard about penny stocks and wondered what why they ignite so much excitement. Investing in stocks that only cost pennies?

Penny Stocks: What They Are & 3 To Watch In The Stock Market Today

BOSTON , Aug. 10, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that management is scheduled to participate in a panel discussion titled "Generative AI & Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine" at the UBS MedTech, Tools and Genomics Summit 2023 on Tuesday, August 15 at 2:00 p.m. Pacific Time.

Ginkgo Bioworks Announces Participation in UBS MedTech, Tools and Genomics Summit 2023

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2023 Earnings Conference Call August 9, 2023 5:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President, Corporate Development Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Steve Mah - Cowen Mark Massaro - BTIG Anna Marie Wagner Good evening. I am Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2023 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.41 per share a year ago.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates

Ginkgo added 21 new Cell Programs to the Foundry platform in Q2 2023 Highlighted continued success selling into large established biotech R&D organizations with recently expanded relationships with Sumitomo, Novo Nordisk, and Merck Ginkgo ended Q2 2023 with approximately $1.1 billion in cash and cash equivalents, providing a strong multi-year runway as Ginkgo continues to drive towards profitability BOSTON , Aug. 9, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2023. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Second Quarter 2023 Financial Results

Merck

Shares in Ginkgo Bioworks jumped more than 7% in pre-market trading following the announcement of their collaboration with Merck & Co Inc (NYSE:MRK). The partnership aims to enhance biologics manufacturing.

Ginkgo Bioworks up 7% in pre-market after inking second Merck deal

Ginkgo Bioworks up 6% in pre-market after inking second Merck deal

Ginkgo Bioworks Holdings Inc. shares DNA, were rising more than 5% in Monday's premarket trading after the company said it was collaborating with Merck & Co. Inc. MRK, -0.69% on improvements in biologic manufacturing. Ginkgo plans to use its abilities in cell engineering, ultra high-throughput multiplexed screening, protein characterization and process optimization to boost yields and drive improvements in production efficiency.

News for Ginkgo Bioworks Holdings Stock (DNA)